The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.
Patients with hematologic disorders undergoing allo-HCT from fully HLA-matched unrelated or related donors after full-intensity conditioning regimen
Age ≥18 years
Karnofsky performance status >70%, see Appendix A
Patients must be able to swallow capsules/tablets
Patients with active inflammatory bowel disease requiring treatment per treating investigator
Patients with a history of gastric bypass surgery
Patients with active Clostridium difficile infection at the time of study enrollment. Active infection is defined as a stool sample positive for Clostridium difficile toxin via enzyme immunoassay (EIA) and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon
Patients with active iron deficiency anemia requiring treatment